Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • Ann235
    Junior Member
    • Mar 2013
    • 2

    Hello from a Sanger sequencer

    Hi,
    My name is Ann, and I'm an old Sanger sequencer getting used to the NGS world. I used to do radioactive (S-35 and P-33) sequencing, ~3-5 days hands on for 750 bp, so the switch to capillaries was incredible then and the switch to millions of reads makes my younger self green with envy. I've always been a mix of molecular biologist with super-user: I build my own Illumina libraries but send them off to a sequencing core and I can work in the Galaxy Web based interface and can explain what I want to a programmer but I cannot program myself. (I tried. I took a series bioinformatics courses including C++and Perl but I'm so slow at programming that I could calculate an e-value by hand faster than I could code it.)

    Enough about me. I have several questions.

    1) I'm curious why Phred values don't seem to be used by de novo NGS sequencing assemblers, or have I just not read the documentation correctly? They seem only to be used to evaluate whether a MiSeq or HiSeq run was good and not to mask or trim individual bases that aren't good. It seems weird to me to throw out an entire read if only few bases are bad.

    2) What are the average %>Q30 for MiSeq and HiSeqs? Normal ranges?
    I realize that longer reads have declining Q30s, but on my first 2 MiSeq runs, as quality controls before HiSeq runs, at 2 x 150s with 96 combinations of dual index adapters, the core told me I had Read 1 96%>Q30 and Read 4 (Read 2 sequencing primer 2) 92%>Q30 with ~12 million paired end reads PF. On my second run, with 1 index, I had 2 x 250 at about the same # of reads ~94% and ~90% respectively. They said those values were high, I'm just trying to get a feel for how high. The Sequence Analysis Viewer shows that most of the cycles are well above Q35 with the 2 index sets (8 cycles each index Read 2 and 3) in the middle dropping to Q30.

    Thanks in advance,
    Ann
  • JackieBadger
    Senior Member
    • Mar 2009
    • 385

    #2
    Originally posted by Ann235 View Post
    Hi,


    1) I'm curious why Phred values don't seem to be used by de novo NGS sequencing assemblers, or have I just not read the documentation correctly?
    Lots of assemblers. Most use Phred scores in assembly and SNP ID

    Comment

    Latest Articles

    Collapse

    • SEQadmin2
      Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
      by SEQadmin2


      Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

      The systematic characterization of the human proteome has
      ...
      07-20-2026, 11:48 AM
    • SEQadmin2
      Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
      by SEQadmin2



      Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
      ...
      07-09-2026, 11:10 AM
    • SEQadmin2
      Cancer Drug Resistance: The Lingering Barrier to Rising Survival
      by SEQadmin2



      Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

      There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
      07-08-2026, 05:17 AM

    ad_right_rmr

    Collapse

    News

    Collapse

    Topics Statistics Last Post
    Started by SEQadmin2, Yesterday, 11:41 AM
    0 responses
    10 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 07-20-2026, 11:10 AM
    0 responses
    23 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 07-13-2026, 10:26 AM
    0 responses
    37 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 07-09-2026, 10:04 AM
    0 responses
    46 views
    0 reactions
    Last Post SEQadmin2  
    Working...